Montreal, Canada - December, 2009- BiolActis, a biotechnology company focused on the management of obesity-related metabolic disorders, reports its results of its latest clinical study on metabolic syndrome in meetings and events, among some, the 6^th NIZO conference in Papendal, The Netherlands on September 30, Natural Products Expo East, the Cardiometabolic health congress in Boston and the World Diabetes Congress of the International Diabetes Federation in Montreal (October 18-22) and Supply Side West last week.

BiolActis announces that the trial designed to assess the hypothesis that MPM exerts multiple metabolic impact in humans exhibiting the metabolic syndrome is positive.  All participants assigned to the MPM group benefited from MPM in either maintaining or improving metabolic health in contrast to the placebo.  Metabolic syndrome is a group of risk factors associated with obesity that may increase the risk of developing diabetes or cardiovascular disease. According to the American Heart Association, metabolic syndrome affects an estimated 47 million Americans.

MPM which stands for Multi Plex Matrix, a discovery made by BiolActis (Patent pending - Simard E and Lemieux P. et al.), was tested in a large, multi-centered (15), randomized, double-blind, placebo-controlled, parallel group study. The study was conducted by a CRO in Germany according to GCP guidelines.  Two hundred participants diagnosed and exhibiting high triglyceride (TG) levels (> 150 mg/dL) combined to at least 2 other features defining the syndrome (low HDL, abdominal obesity, high blood pressure and high fasting blood glucose) were included in the trial and randomized  to take 7gr bid of MPM in a spoonable yogurt format for three months.  In the end, the patient disposition was excellent and in this respect, the trial was well run according to protocol, the randomization was effective with well balanced groups at baseline.

We are extremely excited to announce publically that the primary end-point (TG) was met which means that a significant TG reduction (p < 0.007) by treatment was detected when all patients are considered (ITT population) (an average reduction of -15% vs placebo).  In addition, the trial data review revealed that the MPM provide with a positive and beneficial impact on main features defining the metabolic syndrome such as an improved fasting glucose level, body weight and systolic blood pressure, concluded Pierre Lemieux, Ph.D., President and CEO.  It is important to note that during the course of this study, no notable safety problems were recorded in the active MPM group and the investigational product was rated as well-tolerated by most of the study participants, added Dr. J-F. Lapointe, Director of Clinical Affairs.  

The data to be disclosed and submitted in full for publication represent a major event and milestone in the life of BiolActis added Dr. Lemieux who is now gearing up the communication strategy and market authorizations for a commercial launch and to attract a major industrial partner interested in product designed for the management of obesity-related disorders.

CONTACT:     Dr. Pierre Lemieux, President and CEO, Technologie BiolActis, Inc.
Tel.: 450 781 1303, plemieux@biolactis.com